Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
Authors:
- Kohei KobatakeKKKohei Kobatake
- Keisuke GotoKGKeisuke Goto
- Yohei SekinoYohei Sekino
- Kazuma YukihiroKYKazuma Yukihiro
- Miki NaitoMNMiki Naito
- Kenshiro TakemotoKTKenshiro Takemoto
- Shunsuke MiyamotoSMShunsuke Miyamoto
- Hiroyuki KitanoHKHiroyuki Kitano
- Akihiro GorikiAGAkihiro Goriki
- Keisuke HiedaKHKeisuke Hieda
- Nobuyuki HinataNHNobuyuki Hinata
Open Access
- 30 June 2026
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Primary resistant disease (PRD) to immuno-oncology plus vascular endothelial growth factor receptor inhibitor (IOVE) therapy is a critical unmet need in metastatic renal cell carcinoma (mRCC), yet its clinical and molecular features remain poorly defined. We provide the first integrated clinical and genomic characterization of PRD, combining two complementary, non-overlapping cohorts: a real-world clinical cohort of 159 patients (Hiroshima Cancer Registry Project, H-CARP) and a national genomic database (Center for Cancer Genomics and Advanced Therapeutics, C-CAT). PRD (n = 20 [12.6%]) defined a distinct high-risk group with markedly shorter progression-free survival, PFS2, and overall survival (OS) and a median OS of 8.5 months. Notably, liver metastasis was a strong, readily available independent predictor of PRD (odds ratio 4.99; p = 0.011), enabling early risk stratification, and non-clear cell histology was enriched among PRD. The comparable OS with or without subsequent therapy underscores an urgent need for novel strategies. Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.Keywords
This publication has 38 references indexed in Scilit:
- Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinomaCancer Treatment Reviews, 2025
- Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinomaAnnals of Oncology, 2024
- Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Targeted Oncology, 2024
- Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up dataCancer Immunology, Immunotherapy, 2024
- Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell CarcinomaClinical Genitourinary Cancer, 2023
- Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibitionDiscover Oncology, 2023
- Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinomaCancer Medicine, 2023
- Real world data on IO-based therapy for metastatic renal cell carcinomaJournal of Cancer Research and Clinical Oncology, 2022
- Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell CarcinomaJAMA Network Open, 2022
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaAnnals of Oncology, 2020